DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

Novo Nordisk (NYSE: NVO)

43.67 -0.13 (-0.30%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NVO $43.67 -0.30%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $43.83
Previous Close $43.80
Daily Range $43.37 - $43.88
52-Week Range $35.92 - $49.11
Market Cap $120.1B
P/E Ratio 0.00
Dividend (Yield) $0.61 (1.4%)
Ex-Dividend Date
Dividend Pay Date
Volume 430,974
Average Daily Volume 1,335,870
Current FY EPS $1.70





Novo Nordisk (NVO) Description

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals. Website:

News & Commentary

The Newest FDA-Approved Obesity Drug Is Also the Oldest

Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.

Is Vivus Headed Towards An Unfortunate Ending?

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

European ADRs Lower on Pharmaceutical Stock Contraction

This May Be the Fastest-Growing Big Pharma Next Year (Hint: It Isn't Johnson & Johnson)

Novo Nordisk is expected to increase sales faster than Johnson & Johnson in 2015.

Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog

Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog

Heavy Volume And Pre-Market Movement For Novo Nordisk A/S (NVO)

Another Take On Why Timing The Market Does Not Work

See More NVO News...

NVO's Top Competitors

NVO $43.67 (-0.30%)
Current stock: NVO
JNJ $105.06 (0.45%)
Current stock: JNJ
NVS $94.10 (0.20%)
Current stock: NVS
RHHBY $34.23 (-0.16%)
Current stock: RHHBY